Institutional members access full text with Ovid®

Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis

Solomon, Marc M.a,b; Lama, Javier R.e; Glidden, David V.b; Mulligan, Kathleenb; McMahan, Vanessaa; Liu, Albert Y.b,c; Guanira, Juan Vicented; Veloso, Valdilea G.f; Mayer, Kenneth H.g; Chariyalertsak, Suwath,i; Schechter, Mauroj; Bekker, Linda-Gailk; Kallás, Esper Georgesl,m; Burns, David N.n; Grant, Robert M.a,b; for the iPrEx Study Team

doi: 10.1097/QAD.0000000000000156
Clinical Science

Objective: Tenofovir disoproxil fumarate (TDF) pre-exposure prophylaxis decreases sexual acquisition of HIV infection. We sought to evaluate the renal safety of TDF in HIV-uninfected persons.

Design and methods: The Iniciativa Profilaxis Pre-Exposición (iPrEx) study randomly assigned 2499 HIV-seronegative men and transgender women who have sex with men (MSM) to receive oral daily TDF coformulated with emtricitabine (FTC/TDF) or placebo. Serum creatinine and phosphorus during randomized treatment and after discontinuation were measured, and creatinine clearance (CrCl) was estimated by the Cockcroft–Gault equation. Indicators of proximal renal tubulopathy (fractional excretion of phosphorus and uric acid, urine protein, and glucose) were measured in a substudy.

Results: There was a small but statistically significant decrease in CrCl from baseline in the active arm, compared to placebo, which was first observed at week 4 (mean change: −2.4 vs. −1.1 ml/min; P = 0.02), persisted through the last on-treatment visit (mean change: +0.3 vs. +1.8 ml/min; P = 0.02), and resolved after stopping pre-exposure prophylaxis (mean change: −0.1 vs. 0.0 ml/min; P = 0.83). The effect was confirmed when stratifying by drug detection. The effect of FTC/TDF on CrCl did not vary by race, age, or history of hypertension. There was no difference in serum phosphate trends between the treatment arms. In the substudy, two participants receiving placebo had indicators of tubulopathy.

Conclusions: In HIV-seronegative MSM, randomization to FTC/TDF was associated with a very mild nonprogressive decrease in CrCl that was reversible and managed with routine serum creatinine monitoring.

aThe Gladstone Institutes

bUniversity of California

cBridge HIV, San Francisco Department of Public Health, San Francisco, USA

dInvestigaciones Medicas en Salud

eAsociación Civil Impacta Salud y Educación, Lima, Peru

fInstituto de Pesquisa Clinica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

gFenway Institute, Fenway Health, Boston, USA

hResearch Institute for Health Sciences

iDepartment of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

jProjeto Praça Onze, Hospital Escola São Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

kDesmond Tutu HIV Centre and Department of Medicine, University of Cape Town, Cape Town, South Africa

lDivision of Clinical Immunology and Allergy, School of Medicine, University of São Paulo

mInstituto de Investigação em Imunologia, CEP 05403–900 Cerqueira Cesar, São Paulo, Brazil

nNational Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.

Correspondence to Robert M. Grant, MD, 1650 Owens Street, San Francisco, CA 94158, USA. Tel: +1 415 350 8909; e-mail: rgrant@gladstone.ucsf.edu

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (http://www.AIDSonline.com).

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/3.0.

Received June 25, 2013

Accepted November 14, 2013

© 2014 Lippincott Williams & Wilkins, Inc.